Quick Answer
LENZ Therapeutics, Inc. reported Cash and Equivalents of $25.18 million for fiscal year 2025.
LENZ Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $25.18M | +24.9% |
| 2024 | $20.16M | -42.6% |
| 2023 | $35.14M | -26.4% |
| 2022 | $47.73M | -87.3% |
| 2021 | $376.98M | +1805.7% |
| 2020 | $19.78M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $25.40M | -38.1% | -32.5% |
| June 30, 2025 | $37.61M | -55.2% | +63.2% |
| March 31, 2025 | $23.04M | -88.5% | +14.3% |
| December 31, 2024 | $20.16M | -42.6% | -50.9% |
| September 30, 2024 | $41.05M | -77.6% | -51.2% |
| June 30, 2024 | $84.03M | -34.6% | -58.1% |
| March 31, 2024 | $200.36M | +187.0% | +470.2% |
| December 31, 2023 | $35.14M | -26.4% | -80.8% |
- LENZ Therapeutics, Inc. showed an increase of +24.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, LENZ Therapeutics, Inc.’s cash and equivalents has grown by 27.3% (from $19.78 million to $25.18 million).
- The most recent figure is from LENZ Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: